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ABSTRACT
Objectives Gout is a highly inﬂammatory but self-
limiting joint disease induced by the precipitation of
monosodium urate (MSU) crystals. While it is well
established that inﬂammasome activation by MSU
mediates acute inﬂammation, little is known about the
mechanism controlling its spontaneous resolution. The
aim of this study was to analyse the role of neutrophil-
derived microvesicles (PMN-Ecto) in the resolution of
acute gout.
Methods PMN-Ecto were studied in a murine model of
MSU-induced peritonitis using C57BL/6, MerTK−/− and
C5aR−/− mice. The peritoneal compartment was
assessed for the number of inﬁltrating neutrophils
(PMN), neutrophil microvesicles (PMN-Ecto), cytokines
(interleukin-1β, TGFβ) and complement factors (C5a).
Human PMN-Ecto were isolated from exudates of
patients undergoing an acute gouty attack and
functionally tested in vitro.
Results C5a generated after the injection of MSU
primed the inﬂammasome for IL-1β release. Neutrophils
inﬁltrating the peritoneum in response to C5a released
phosphatidylserine (PS)-positive PMN-Ecto early on in the
course of inﬂammation. These PMN-Ecto in turn
suppressed C5a priming of the inﬂammasome and
consequently inhibited IL-1β release and neutrophil
inﬂux. PMN-Ecto-mediated suppression required surface
expression of the PS-receptor MerTK and could be
reproduced using PS-expressing liposomes. In addition,
ectosomes triggered the release of TGFβ independent of
MerTK. TGFβ, however, was not sufﬁcient to control
acute MSU-driven inﬂammation in vivo. Finally, PMN-
Ecto from joint aspirates of patients with gouty arthritis
had similar anti-inﬂammatory properties.
Conclusions PMN-Ecto-mediated control of
inﬂammasome-driven inﬂammation is a compelling
concept of autoregulation initiated early on during PMN
activation in gout.
INTRODUCTION
Gout is a highly inﬂammatory arthritis induced by
the precipitation of monosodium urate (MSU) crys-
tals in articular joints. Even without intervention,
acute gouty arthritis (GA) usually resolves spontan-
eously within a few days leaving minimal residual
damage to the joint. What drives this timely reso-
lution of gout, however, is not yet clear.
The early inﬂammatory phase of gout is charac-
terised by the production of the proinﬂammatory
cytokine interleukin-1β (IL-1β) and the inﬁltration
of neutrophils into the joint space. IL-1β is the
principle driving force of gouty inﬂammation and
is released as a consequence of NLRP3
inﬂammasome assembly and caspase 1 activation.1
The underlying mechanism behind the resolution
of gout must therefore interfere with the release of
IL-1β.
Previous studies indicate that the generation of
apoptotic leucocytes and their clearance by macro-
phages may play a key role in resolving gout.2 3
The recognition of phosphatidylserine (PS) on the
surface of apoptotic cells and the release of TGFβ
upon their clearance are strong anti-inﬂammatory
cues that can suppress an inﬂammatory response.4
PS-positive surfaces can engage the MerTK recep-
tor initiating the transcription of suppressor of
cytokine signalling (SOCS) 3.5–7 High levels of
SOCS3 expression in synovial tissues as well as ele-
vated levels of TGFβ in the synovial ﬂuids of
patients during the resolution phase of gout have
been reported.8 Little is however known about how
and where the inﬂammasome is regulated.
We previously established that human neutrophils
stimulated by complement C5a or bacterial peptide
fMLP (formyl-methionyl-leucyl-phenylalanine) in
vitro release microvesicles (ectosomes) from their
surface.9 These ectosomes express PS and are
capable of inducing the release of TGFβ by
monocyte-derived macrophages. In vitro,
neutrophil-derived ectosomes have been shown to
suppress the response to TLR ligands in monocyte-
derived macrophages and dendritic cells.10
The aim of this study was to determine whether
the anti-inﬂammatory effects of ectosomes extend
to the NLRP3 inﬂammasome, whether ectosomes
are found in vivo and whether they take part in the
early resolution of gouty inﬂammation.
MATERIALS AND METHODS
Generation and analysis of PMN-Ecto
and BM-Ecto
Mouse PMN-Ecto were derived from inﬂamed
peritonea. The peritoneal cavity was lavaged with
5 mL PBS-1%FCS, 6–10 h after intraperitoneal
injection of 3 mg MSU crystals, and the lavage ﬂuid
sequentially centrifuged to separate cells (350 g/100/
4°C), cell debris (3000 g/100/4°C) and ﬁnally
PMN-Ecto (50.000 g/400/4°C). The ﬁnal pellet was
diluted in 0.2 mm ﬁltered buffers and analysed by
ﬂow cytometry. PMN-Ecto were counted using
Trucount beads (BD Biosciences, Allschwill,
Switzerland) as follows: (% of total microvesicles/%
of beads)×(absolute number of beads)×(% of
annexin V+, Gr-1+ double positive events). Mouse
bone marrow-derived ectosomes (BM-Ecto) were
prepared from bone marrow cells obtained by
ﬂushing femurs and tibias of B6 mice. Erythrocytes
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were removed by hypotonic lysis and the remaining myeloid
cells stimulated with 1 mM fMLP (Sigma, St Louis, Missouri,
USA) or 10 ng/mL mouse recombinant C5a (BD Pharmingen) in
RPMI for 30 min at 37°C. The supernatant was sequentially
centrifuged as above. Where indicated, BM-Ecto were stained
with 5 mM CFSE (Molecular Probes, Zug, Switzerland). Human
PMN-Ecto were isolated by sequentially centrifuging joint exu-
dates from patients with gout or control patients with osteoarth-
ritis (OA). Flow cytometry was performed using a CyanADP
cytometer (Beckman Coulter, Nyon, Switzerland). Data were
analysed using FlowJo Software (TreeStar, San Jose, California,
USA).
Cell culture conditions, ELISA and western blot
Resident peritoneal macrophages were harvested by peritoneal
lavage and plated at 2×106/well. To achieve full inﬂammasome
activation in vitro, cells were ﬁrst primed with 10 ng/mL ultra-
pure LPS (Invivogen, Toulouse, France) or 10 ng/mL mouse
recombinant C5a (BD) for 10 h, washed and subsequently sti-
mulated with 100 mg/mL MSU. Macrophages were treated with
BM-Ecto (1×108 BM-Ecto/2×106 macrophages) or liposomes
containing either phosphatidylserine (PS) or control phosphat-
idylcholine (PC) (1×108 liposomes/2×106 macrophages) for
10 min either prior to LPS priming or prior to MSU stimula-
tion. Cell extracts and cell culture supernatants were prepared
for western blotting as described previously.11 SOCS3 protein
expression was analysed by densitometry and normalised to
actin using Image Lab software (Biorad, Munich, Germany).
Cell culture supernatants and peritoneal lavages were analysed
for IL-1β, IL-10, IL-1Ra and TGFβ using the IL-1β, IL-10
OptEIA (BD Pharmingen), IL-1Ra (R&D, DY480) and TGFβ1
(eBiosciences, Vienna, Austria) ELISA kits, respectively, accord-
ing to the manufacturer’s instructions.
Experimental peritonitis
Mice were treated with an intraperitoneal injection of 2×107 BM-
Ecto/PMN-Ecto or comparable amounts of PS or control PC
liposomes 2 h prior to intraperitoneal stimulation with 3 mg MSU
crystals. Control groups received Ecto followed by 0.9% NaCl or
received the stimulus preceded by an injection of 0.9% NaCl
instead of Ecto. At the indicated time points following induction
of peritonitis, mice were sacriﬁced by CO2-inhalation and periton-
eal lavage was performed with 5 mL PBS-1% FCS. The lavage
ﬂuid was ﬁltered (70 μm), washed and contaminating red blood
cells removed by hypotonic lysis. Leucocytes were counted with
an automated cell counter (Beckman Coulter, Nyon, Switzerland).
Peritoneal leucocytes were phenotyped by ﬂow cytometry follow-
ing surface staining with the indicated antibodies (see online sup-
plementary ﬁgure S1A).
For detailed methods see online supplementary material.
RESULTS
Bone marrow-derived ectosomes suppress inﬂammasome
activation in vitro
We ﬁrst set out to ﬁnd a source of murine ectosomes using B6
wild type (WT) bone marrow cells as a close approximation of
neutrophils. BM-Ecto were isolated by sequentially centrifuging
supernatants of bone marrow cells stimulated with fMLP. Flow
cytometric analysis identiﬁed intact vesicles that were able to
retain CFSE. Further characterisation revealed the expression of
the neutrophil marker Gr-1 and surface exposure of PS (assessed
by annexin V staining) on approximately 70–80% of intact
BM-Ecto (ﬁgure 1A). Consistent with data from human
neutrophil-derived ectosomes,9 electron microscopy of BM-Ecto
preparations revealed round shaped vesicles with a size of 50–
500 nm (ﬁgure 1B).
We next asked whether BM-Ecto suppress MSU-induced
inﬂammasome activation of resident peritoneal macrophages in
vitro. Inﬂammasome activation in vitro is a two-step process
that requires priming with a TLR ligand (LPS)12 prior to
stimulation with a speciﬁc inﬂammasome activator (MSU)
(ﬁgure 1C). Whereas upregulation of pro-IL-1β and NALP3
components in cells is the measure of successful priming, release
of mature IL-1β along with the caspase 1 subunits p20 or p10
deﬁnes efﬁcient inﬂammasome stimulation.1 13 14 To determine
whether BM-Ecto interfere with inﬂammasome activation,
BM-Ecto were given to macrophages either prior to LPS
priming or prior to stimulation with MSU (ﬁgure 1D) once all
LPS priming events (pro-ILβ and NALP3 upregulation) had
taken place.
The release of IL-1β into culture supernatants was signiﬁ-
cantly suppressed when macrophages received BM-Ecto either
prior to LPS priming or MSU stimulation (ﬁgure 1E), indicating
that BM-Ecto acted on both phases of inﬂammasome activation.
Immunoblots of cell extracts (ﬁgure 1F) and cell culture super-
natants (ﬁgure 1F) revealed that incubation of macrophages
with BM-Ecto prior to LPS impaired efﬁcient priming (less
NALP3 and pro-IL-1β expression) and subsequently rendered
macrophages unresponsive to MSU stimulation (no caspase 1
p20/10 and IL-1β release). The addition of BM-Ecto after LPS
priming resulted in partial suppression of the MSU response (no
caspase 1 p20 and less IL-1β), consistent with data obtained by
ELISA (ﬁgure 1E). These results indicated that BM-Ecto contain
inﬂammasome activation in vitro by suppressing LPS priming
and MSU stimulation independently of each other.
The anti-inﬂammatory effects of Ecto have been attributed to
their surface expression of PS15 analogous to what has been
reported for apoptotic cells.4 5 7 We therefore asked whether the
in vitro effects of BM-Ecto could be reproduced by size-matched
liposomes expressing PS. Following our in vitro stimulation
protocol (ﬁgure 1D) macrophages were treated with equal
amounts (approximately 1×108) of PS or control PC liposomes.
While PS liposomes interfered with LPS priming (ﬁgure 1G, H,
cell extracts) and MSU stimulation (ﬁgure 1G, H, cell superna-
tants), PC liposomes failed to attenuate the inﬂammasome
response at any level. These results suggested that PS is involved
in the inhibition of inﬂammasome activation by BM-Ecto.
C5a and MSU-induced inﬂammation
Inﬂammasome activation in macrophages is functionally limited
by low expression of pro-IL-1β and therefore requires some
form of priming.1 12 During gout, however, activation of the
NLRP3 inﬂammasome occurs in a sterile environment and has
been shown to be independent of Toll-like-receptor 4.16
Therefore the use of LPS as a priming agent in vitro does not
accurately reﬂect what occurs in vivo. MSU crystals are known
to activate complement by assembling a functional C5 conver-
tase complex at the crystal surface, which results in the gener-
ation of active C5a.17 C5a fragments have been reported to
activate NFκB.18–20 Given that the injection of MSU alone can
trigger IL-1β release,1 21 we hypothesised that C5a generated by
MSU is responsible for inﬂammasome priming in vivo.
MSU crystals generated C5a in the presence of plasma, which
in turn primed the inﬂammasome via the C5aR leading to the
release of IL-1β upon MSU stimulation of macrophages in vitro
(ﬁgure 2A). BM-Ecto were capable of suppressing IL-1β release
from macrophages stimulated by MSU in the presence of plasma
(ﬁgure 2B) and macrophages primed with C5a and subsequently
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Figure 1 Characterisation and in vitro properties of BM-Ectosomes. (A) Flow cytometric characterisation of bone marrow-derived ectosomes
(BM-Ecto). CFSE-positive events (representing intact vesicles) were analysed for surface expression of Gr-1 and phosphatidylserine (PS; using annexin
V) (upper lane, left to right). Controls are (lower lane, left to right): annexin buffer alone, CFSE threshold set on sonicated BM-Ecto previously
stained with CFSE, BM-Ecto stained with annexin V and IgG1 isotype in PBS. FSC denotes forward scatter, SSC side scatter, respectively. Numbers
indicate % positive BM-Ecto (B) Morphology of BM-Ecto (size bar 100 nm) and (C) monosodium urate (MSU) crystals (size bar 50 mm) as
determined by transmission electron microscopy and light microscopy, respectively. (D) In vitro stimulation protocol. B6 peritoneal macrophages were
primed with LPS for 10 h and subsequently stimulated with 100 mg/mL MSU for 4 h. BM-Ecto (1×108 BM-Ecto /2×106 macrophages) were given
either prior (BM-Ecto+LPS>MSU) or after (LPS>BM-Ecto+MSU) LPS priming as outlined. Alternatively, PS-liposomes or control PC-liposomes were
given instead of BM-Ecto. (E and G) IL-1β in cell culture supernatants determined by ELISA. n=4 per group. (F and H) Cell extracts (XT) and
supernatants (SN) were analysed for the presence of NALP3, pro-IL-1β, IL-1β and active caspase 1 (p20 and p10) by western blot. Data in A, F and
H are representative of three independent experiments. ***p<0.001. Mean±SEM is shown.
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stimulated with MSU (ﬁgure 2C). These results suggested that
C5a is essential for inﬂammasome activation by MSU and that
BM-Ecto inhibit C5a-mediated inﬂammasome priming.
To study inﬂammasome activation in vivo, we next adopted a
murine model of MSU-induced peritonitis.21 We ﬁrst analysed
the course of the inﬂammatory response following intraperito-
neal injection of MSU. There was an almost immediate and
steep rise of C5a 15 min after introducing MSU into the peri-
toneum (ﬁgure 2D). The generation of C5a was followed by the
release of IL-1β in the peritoneum peaking 4 h after MSU injec-
tion (ﬁgure 2D). The release of C5a and IL-1β triggered a rise
in blood neutrophils (not shown), which then inﬁltrated the
peritoneal compartment reaching a maximum 14 h after stimu-
lation (ﬁgure 2D). In accordance with our in vitro results, the
release of IL-1β in response to MSU was signiﬁcantly impaired
in C5aR deﬁcient mice (ﬁgure 2E).
We next determined whether Ecto are released by inﬁltrating
neutrophils during MSU-induced peritonitis. At various time
Figure 2 Role of C5a in monosodium urate (MSU)-induced inﬂammation. (A) Inﬂammasome activation by MSU is dependent on C5a in vitro.
Generation of C5a and IL-1β release from C5aR+/+ or C5aR−/− peritoneal macrophages stimulated with 100 mg/mL MSU in the presence of 25%
plasma for 14 h in vitro. n=6 per group pooled from two independent experiments. (B and C) BM-Ecto inhibit C5a-mediated inﬂammasome
activation in vitro. (B) BM-Ecto were given to B6 macrophages prior to stimulation with 100 mg/mL MSU in the presence of 25% plasma for 14 h or
to (C) macrophages primed with 10 ng/mL recombinant mouse C5a for 10 h and subsequently stimulated with 100 mg/mL MSU for 4 h. IL-1β
release, pro-IL-1β and NALP3 expression were analysed as in ﬁgure 1. n=6 per group pooled from two independent experiments (ELISA), western
blots representative of two independent experiments. (D) Kinetics of MSU-induced peritonitis. B6 mice received an intraperitoneal injection of 3 mg
MSU. At the indicated time points thereafter, peritonea were lavaged and inﬁltrating cells phenotyped by ﬂow cytometry PMN were identiﬁed as
CD45+, CD11b+, Ly6C+, Ly6G+ cells. Peritoneal concentrations of C5a and IL-1β were determined by ELISA. n=4/time point pooled from two
independent experiments. (E) Inﬂammasome activation is C5a-dependent in vivo. Concentration of IL-1β in the peritoneal lavage ﬂuid of C5aR+/+
and C5aR−/− mice 4 h after injection of 3 mg MSU. n=5 pooled from two independent experiments. (F) Release of BM-Ecto requires the C5aR.
1×107 bone marrow cells were stimulated with 10 ng/mL recombinant mouse C5a for 30 min at 37°C. BM-Ecto were isolated from the supernatant
as indicated in Methods. n=5 pooled from two independent experiments. *p<0.05, ***p<0.001. Mean±SEM is shown.
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points following MSU stimulation, Ecto were isolated from peri-
toneal lavages by sequential centrifugation. Using ﬂow cytome-
try, surface staining with annexin V and anti-Gr-1 identiﬁed
them as PS-positive microvesicles of neutrophil origin (see
online supplementary ﬁgure S1B). These neutrophil ectosomes
(PMN-Ecto) were found to be present in signiﬁcant numbers,
reaching up to 1.5×107 in the peritoneum 8 h after MSU stimu-
lation (ﬁgure 2D). The kinetics of PMN-Ecto suggested that
their release is an early event of neutrophil activation. Given
that bone marrow cells release BM-Ecto in response to C5a,
complement activation is the likely trigger for ectosome release
in gout (ﬁgure 2F).
Administration of Ecto attenuates MSU-induced
inﬂammation in vivo
To determine whether Ecto have anti-inﬂammatory properties in
vivo, the peritoneal compartment was pretreated with 2×107
Ecto 2 h prior to the intraperitoneal injection of MSU. The Ecto
used to precondition the peritoneum were either BM-Ecto iso-
lated from ex vivo stimulated bone marrow cells or PMN-Ecto
isolated from the lavage ﬂuid of MSU-inﬂamed peritonea. The
quantity (2×107) of preinjected BM-Ecto and PMN-Ecto corre-
sponded to the maximum number of PMN-Ecto recovered
during MSU-induced peritoneal inﬂammation (ﬁgure 2D).
Pretreatment with PMN-Ecto or BM-Ecto resulted in a
twofold suppression of IL-1β release in response to MSU (ﬁgure
3A) and subsequently a threefold decrease in the number of
inﬁltrating neutrophils into the peritoneal compartment 14 h
after stimulation (ﬁgure 3B). Taken together, these results
indicated that Ecto from two independent sources can suppress
inﬂammation induced by MSU.
The in vivo effects of Ecto can be mimicked by liposomes
expressing PS
To conﬁrm that PS liposomes can act as a surrogate for Ecto in
vivo, approximately 2×107 PS or control PC liposomes were
injected intraperitoneally instead of Ecto 2 h prior to stimulation
with MSU. Pretreatment with PS liposomes resulted in suppres-
sion of IL-1β (ﬁgure 3C) and neutrophil inﬂux into the periton-
eum (ﬁgure 3D) in response to MSU. Injection of control PC
liposomes failed to achieve an anti-inﬂammatory effect.
Suppression by BM-Ecto is MerTK-dependent in vivo
To directly test the involvement of PS in Ecto-mediated
immunosuppression, we next applied our model to mice lacking
the MerTK receptor (MerTK−/−) which is known to bind PS and
relay its signal by inducing SOCS3.7
The peritonea of MerTK−/− and control B6129S (WT) mice
were pretreated with BM-Ecto prior to MSU stimulation.
Whereas pretreatment of WT mice with BM-Ecto led to sup-
pression of IL-1β release (ﬁgure 4A) and neutrophil inﬂux
(ﬁgure 4B) in the peritoneum, the anti-inﬂammatory effects of
BM-Ecto were absent in MerTK−/− mice. Furthermore, 4 h after
intraperitoneal BM-Ecto injection, we observed a
MerTK-dependent induction of SOCS3 in peritoneal macro-
phages (ﬁgure 4C). Of note, inﬂammation induced by MSU in
MerTK−/− mice was signiﬁcantly higher compared with
background-matched WT mice (ﬁgure 4A, B), suggesting that
Figure 3 Administration of
ectosomes attenuates monosodium
urate (MSU)-driven peritoneal
inﬂammation. B6 mice were injected
intraperitoneally with 3 mg MSU.
Where indicated, mice were preinjected
with 2×107 BM-Ecto or PMN-Ecto
intraperitoneally 2 h prior to MSU
stimulation. Alternatively, mice were
preinjected with 75 nM (approximately
2×107) of phosphatidylserine
(PS)-liposomes or phosphatidylcholine
(PC)-liposomes. Control groups
received BM-/PMN-Ecto or PS-/
PC-liposome injections intraperitoneally
followed by NaCl instead of MSU. (A
and C) IL-1β in peritoneal lavage ﬂuid
was determined by ELISA 4 h after
MSU stimulation. (B and D) The
number of inﬁltrating PMN into the
peritoneum 14 h after MSU stimulation
was determined as indicated in
ﬁgure 2D. n=6–8 per group pooled
from at least three independent
experiments, *p<0.05, **p<0.01,
***p<0.001. Mean±SEM is shown.
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endogenously released PMN-Ecto limit the magnitude of
MSU-induced inﬂammation via MerTK in WT mice.
BM-Ecto induce the release of TGFβ
It has been suggested that TGFβ participates in the resolution of
gout in its late stages.22 Therefore, we next asked whether Ecto
induce the release of TGFβ in vivo. Injection of BM-Ecto induced
the release of TGFβ in the peritoneum (ﬁgure 5A). The release of
TGFβ was further enhanced when BM-Ecto primed mice received
MSU (ﬁgure 5A). Since BM-Ecto themselves were not the source
of TGFβ (ﬁgure 5B) and the amount of TGFβ released in vitro by
peritoneal macrophages remained the same regardless of inﬂam-
masome activation (ﬁgure 5C), we hypothesised that the additive
effect of MSU and BM-Ecto on TGFβ release could be due to inﬁl-
trating cells responding to BM-Ecto. Indeed, monocytes and neu-
trophils isolated from MSU inﬂamed peritonea were able to
release TGFβ in response to BM-Ecto in vitro (ﬁgure 5D). To
determine which of these cells contributes the most to the TGFβ
pool in vivo, resident macrophages, inﬁltrating monocytes and
neutrophils from BM-Ecto-treated peritonea were stained for
latency associated peptide (LAP). LAP is part of latent TGFβ and
remains tethered to the surface of macrophages23 and mono-
cytes24 once TGFβ is released and cleaved into its active form.
Whereas expression of LAP in naive resident peritoneal macro-
phages (F480+, CD115+, Ly6C−) was low, LAP progressively
increased over time after intraperitoneal injection of BM-Ecto,
indicating continuous TGFβ release (ﬁgure 5E). Monocytes and
neutrophils are not present in untreated peritonea. Upon intraperi-
toneal MSU stimulation, however, inﬁltrating monocytes (Ly6C+,
F480−, Ly6G−) and, to a lesser extent, neutrophils (Ly6C+,
F480−, Ly6G+) upregulated LAP when the peritoneum was pre-
treated with BM-Ecto prior to MSU (ﬁgure 5E).
Ecto suppress MSU-induced peritonitis independent of TGFβ
We next asked whether TGFβ was necessary for the suppressive
effects of Ecto. In vitro, TGFβ release was independent of
MerTK (ﬁgure 5F). In vivo, signiﬁcant increases in TGFβ were
consistently measured in the peritonea of WT and MerTK−/−
mice pretreated with BM-Ecto (ﬁgure 5G). Moreover, PS lipo-
somes did not induce TGFβ release in vivo (ﬁgure 5H). Since
PS liposomes attenuated the response to MSU (ﬁgure 3C, D)
without inducing TGFβ and BM-Ecto failed to inhibit inﬂamma-
tion in MerTK−/− mice (ﬁgure 4A, B) despite releasing TGFβ
(ﬁgure 5G), TGFβ did not seem to be necessary for
BM-Ecto-mediated resolution of acute gouty inﬂammation. To
conﬁrm that the effect of BM-Ecto was independent of TGFβ,
neutralising anti-TGFβ1 antibody was given intraperitoneally
30 min prior to BM-Ecto. In the presence of TGFβ1-blocking
antibody, BM-Ecto still retained their capacity to suppress
inﬂammation (ﬁgure 5I). Although the blocking of TGFβ1
slightly increased neutrophil inﬂux in response to MSU suggest-
ing that TGFβ may play a role (ﬁgure 5I), the injection of
recombinant mouse TGFβ1 instead of BM-Ecto had no effect
(ﬁgure 5J).
Taken together, these data suggested that Ecto inhibit the
acute inﬂammatory response to MSU predominantly via the
PS-MerTK pathway rather than TGFβ. Although Ecto induced
the release of TGFβ by macrophages and monocytes, MerTK
alone was necessary and sufﬁcient for Ecto to suppress inﬂam-
masome activation in vivo.
PMN-Ecto are present in synovial exudates during gouty
inﬂammation in humans
Lastly, we sequentially centrifuged synovial exudates of patients
with GA and control patients with OA to verify the presence of
microvesicles during gouty attacks in humans. Arthrocentesis
was performed within 1 day after the onset of symptoms. Using
ﬂow cytometry, we found annexin V-positive vesicles expressing
the granulocyte marker CD66b and the neutrophil-speciﬁc
enzyme myeloperoxidase (ﬁgure 6A). Electron micrographs
(ﬁgure 6B) of exudates conﬁrmed the presence of intact vesicles
that were approximately 50 nm in size.
Figure 4 Ecto-mediated
immunosuppression requires MerTK in
vivo. B6/129S (wild type, WT) or
MerTK−/− mice were injected
intraperitoneally with 3 mg
monosodium urate (MSU). Where
indicated, mice were preinjected with
2×107 BM-Ecto intraperitoneally 2 h
prior to MSU stimulation. (A) IL-1β
was determined 4 h after MSU
stimulation in the peritoneal lavage
ﬂuid. (B) The number of inﬁltrating
PMN into the peritoneum 14 h after
MSU stimulation was determined as in
ﬁgure 2D. n=6–8 per group, pooled
from at least three independent
experiments. (C) Suppressor of
cytokine signalling (SOCS3) expression
in peritoneal macrophages of B6/129S
(WT) and MerTK−/− mice determined
by immunoblot 4 h after
intraperitoneal BM-Ecto injection.
Expression of SOCS3 in arbitrary units
of band intensity normalised to actin.
n=2 per group pooled from two
independent experiments. *p<0.05,
**p<0.05. Mean±SEM is shown. n.s.,
not signiﬁcant.
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The amount of PMN-Ecto isolated from gout exudates corre-
lated with the number of inﬁltrating PMN (ﬁgure 6C) and GA
exudates had signiﬁcantly higher numbers of PMN-Ecto com-
pared to OA exudates (ﬁgure 6D). Recovery of neutrophil-
derived ectosomes from synovial exudates of patients during
gouty inﬂammation suggested that PMN-Ecto release occurs
and is relevant in vivo.
In vitro, PMN-Ecto from gout exudates (Gout-Ecto) were able
to induce the release of TGFβ from human monocyte-derived
macrophages (ﬁgure 6E) and inhibited the release of IL-1β by
Figure 5 Ecto induce the release of TGF-β independent of MerTK. (A) TGFβ concentration in peritoneal lavage ﬂuids of B6 mice treated as
outlined in ﬁgure 3 was determined by ELISA. n=6–8 pooled from three independent experiments. (B) Ecto are not the source of TGFβ in vivo.
BM-Ecto lysates were assessed for TGFβ content by immunoblot. Recombinant mouse TGFβ was used as control. (C–E) Cellular source of TGFβ.
Release of TGFβ by B6 (C) resident peritoneal macrophages or (D) monocytes and neutrophils isolated from monosodium urate (MSU)-inﬂamed
peritonea following treatment with C5a, MSU and/or BM-Ecto in vitro as outlined in ﬁgure 2C. (E) Expression of latency associated peptide (LAP) on
B6 macrophages, monocytes and neutrophils isolated either 4 h after intraperitoneal injection of BM-Ecto or 4 h after intraperitoneal injection of
MSU with BM-Ecto pretreatment. Controls received NaCl intraperitoneally (untreated). (F–H) TGFβ release is independent of MerTK. (F) The release
of TGFβ by wild type (WT) and MerTK−/− macrophages treated with BM-Ecto in vitro. n=6/group. TGFβ in peritoneal lavage ﬂuids of (G) B6/129S
(WT) and MerTK−/− mice treated with BM-Ecto or (H) B6 mice treated with liposomes as outlined in ﬁgures 3 and 4 ,respectively. n=6–8/group.
(I and J) Effect of TGFβ in vivo. (I) The effect of neutralising anti-TGFβ1 antibodies on peritoneal PMN inﬂux using 100 mg anti-TGFβ1 injected
intraperitoneally 15 min prior to MSU or 15 min prior to BM-Ecto pretreatment. ( J) The effect of 1 mg recombinant mouse TGFβ1 injected
intraperitoneally instead of BM-Ecto prior to MSU stimulation. *p<0.05, **p<0.01, ***p<0.001. Mean±SEM is shown. n.s., not signiﬁcant.
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macrophages (ﬁgure 6F) treated as outlined in ﬁgure 1D.
Furthermore, in the presence of human plasma, MSU crystals
were able to simultaneously prime and stimulate the inﬂamma-
some. Consistently, MSU failed to prime the inﬂammasome in
the presence of heat inactivated or C5-blocked plasma, conﬁrm-
ing that priming is C5-dependent (ﬁgure 6G). Finally, Gout-Ecto
suppressed IL-1β release in macrophages stimulated by MSU in
the presence of human plasma (ﬁgure 6H).
DISCUSSION
The major ﬁndings of the present study are related to C5a and
PMN-Ecto release in gout. C5a generated by MSU is responsible
for priming the inﬂammasome and consequently for the release
of IL-1β. Furthermore, C5a induces PMN-Ecto release by
inﬁltrating neutrophils and these ectosomes in turn limit inﬂam-
masome priming. Ectosomes achieve their anti-inﬂammatory
effect by engaging the MerTK receptor. The regulation induced
by PMN-Ecto starts almost immediately after the inﬂux of cells
into the peritoneum, indicating that the control of inﬂammation
starts much earlier than presumed until now. Interestingly, the
very cells that are responsible for acute inﬂammation (ie, neutro-
phils), act also as its regulator due to the shedding of ectosomes.
The release of PMN-Ecto is an early phenomenon of neutro-
phil activation.9 In our gout model, PMN-Ecto were released as
early as 2 h after intraperitoneal injection of MSU and their con-
centration peaked at 8 h. To analyse their effect on gouty
inﬂammation, ectosomes were given intraperitoneally prior to
MSU injection. The number of ectosomes injected was
Figure 6 PMN-Ecto present in gout exudates in humans have immunosuppressive properties. PMN-Ecto were isolated from joint aspirates of
patients undergoing a gout attack. (A) Ecto were isolated from joint aspirates as indicated in methods and characterised and counted by ﬂow
cytometry. Annexin V, anti-CD66b and anti-myeloperoxidase (MPO) antibodies identiﬁed them to be of neutrophil origin. Counting was performed
using microbeads. (B) Transmission electron microscopy of PMN-Ecto. Size bar 1 mm (left) and 100 nm (right). (C) Correlation between the number
of inﬁltrating PMN and PMN-Ecto found in gout exudates. Each dot represents a single patient. (D) Concentration of PMN-Ecto in gout (gouty
arthritis, GA) and osteoarthritis (OA) exudates. (E–H) PMN-Ecto isolated from joint aspirates are functional in vitro. (E) Release of TGFβ by human
monocyte-derived macrophages (HMDM) treated with Gout-Ecto (1×108 Gout-Ecto/2×106 macrophages). n=7 pooled from two independent
experiments. (F) Suppression of IL-1β release by HMDM treated with Gout-Ecto following the in vitro protocol outlined in ﬁgure 1D. (G) IL-1β release
upon 14 h stimulation of HMDM with 100 mg/mL monosodium urate (MSU) in 25% human plasma (untreated), heat inactivated plasma (heat
inactivated) or C5-blocked plasma (αC5). (F and G) n=6 pooled from three independent experiments. (H) Suppression of IL-1β release by HMDM
treated with Gout-Ecto and stimulated as outlined in (G). ***p<0.001. Mean±SEM is shown.
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physiological and the amount was set at the maximum number
of PMN-Ecto recovered from the peritoneum after MSU stimu-
lation. Since ectosomes bind back to cells9 and are continuously
cleared,25 the recovery of 1.5×107 PMN-Ecto is likely an
underestimation of the total amount of ectosomes shed during
the course of MSU peritonitis.
Previous studies have already suggested that PS expressed on
apoptotic cells3–5 7 and ectosomes26 contribute to the resolution
of inﬂammation. PS has been shown to mediate anti-
inﬂammatory signals via the MerTK receptor.5 7 MerTK activa-
tion leads to induction of SOCS36 and in turn to suppression of
TLR-induced cytokine release.5 7 15 In accordance with these
studies, we could conﬁrm that PS-expressing ectosomes suppress
LPS priming of the NLRP3 inﬂammasome in vitro. LPS
priming, however, is not required for the inﬂammatory response
to MSU in vivo and is therefore merely used to model inﬂam-
masome activation in vitro.16 In addition to activating the
inﬂammasome, MSU crystals activate the complement cascade
by assembling a C5 convertase on their surface.17 27 We could
conﬁrm that C5a generated by MSU is the main inﬂammasome
priming agent in gout in vivo.28 The anti-inﬂammatory effect of
PMN-Ecto was therefore not limited to the inhibition of TLR
stimuli, but extended to C5a and C5aR signalling as well.
Furthermore, C5a was able to prime the inﬂammasome and
limit its activation by inducing the release of PMN-Ecto, thus
forming the basis of an autoregulatory negative feedback loop
in gout.9 This mechanism may apply to other crystal arthropa-
thies such as those caused by calcium pyrophosphate dihydrate
and hydroxyapatite crystals, since Ecto suppress calcium pyro-
phosphate dihydrate and hydroxyapatite-induced IL-1β release
as well (see online supplementary ﬁgure S1C).
Whereas studies using liposomes suggested that PS-positive vesi-
cles could downregulate inﬂammation, involvement of PS was con-
ﬁrmed in mice deﬁcient for the PS receptor MerTK. Furthermore,
the higher degree of inﬂammation in MerTK−/− compared with
WT mice suggested that PS expressed on Ecto provides baseline
suppression in gouty inﬂammation. Of note, high expression of
SOCS3 in synovial tissue has been found in patients during the
acute phase of gout,8 further supporting the notion that the
PS-MerTK axis plays a role in limiting gouty inﬂammation.
TGFβ is considered to play an active role in the resolution of
gout.8 29 30 Levels of TGFβ have been found to progressively
increase in synovial ﬂuids of patients with gout after an attack,
suggesting that TGFβ may be involved in late phases of reso-
lution.8 22 We demonstrated that ectosomes trigger the release
of TGFβ in vitro and in vivo. These ﬁndings are consistent with
other studies that have shown release of TGFβ by macrophages4
or neutrophils3 in response to apoptotic cells and ectosomes.26
In vivo, however, neither treatment with recombinant mouse
TGFβ1 (ﬁgure 5J), nor the release of TGFβ by ectosomes in the
absence of PS-MerTK activation (ﬁgure 5G) was sufﬁcient to
control the acute inﬂammatory response to MSU. Furthermore,
PS-liposomes alone could reproduce the ectosome effect
without inducing the release of TGFβ (ﬁgure 3C-D, ﬁgure 5H)
and TGFβ blocking did not compromise the ability of BM-Ecto
to suppress inﬂammation (ﬁgure 5I). These ﬁndings argue
against a role for TGFβ in the early phase of gout. Given that
patients with gout with TGFβ polymorphisms frequently pro-
gress to more advanced disease states, TGFβ may play a role in
chronic gout and affect the rate of progression rather than reso-
lution of acute attacks.31 Aside from TGFβ, IL-10 and IL-1Ra
have also been associated with anti-inﬂammatory effects, but
they were not induced by ectosomes in the MSU peritonitis
model (see online supplementary ﬁgure S1D–F).32–34
Recently, the resolution of gout has been associated with
another phenomenon of neutrophil activation, the release of
neutrophil extracellular traps (NETs).35 NETs were shown to
degrade proinﬂammatory chemokines by clustering serine pro-
teases such as proteinase 3 and neutrophil elastase. In our
model of acute gout we could not measure signiﬁcant increase
of cell-free DNA or NETs (see online supplementary ﬁgure
S1G) and the treatment with DNAse I did not signiﬁcantly
alter the outcome of MSU-induced inﬂammation (see online
supplementary ﬁgure S1H). Although NETs did not play a
role in this model, the degradation of chemokines by pro-
teases may still be relevant, since PMN-Ecto actively recruit
proteinase 3and neutrophil elastase from ﬂuid phase to their
surface.9 36 PMN-Ecto may not only suppress IL-1β release
upon MSU stimulation, but potentially also degrade IL-1β
once it has been released. This could possibly explain the
higher efﬁcacy of PMN-Ecto compared with liposomes, which
carry no enzymes (ﬁgure 3B, D).
A limitation of our study was the exclusive use of the MSU
peritonitis model. It would be of interest to assess whether ecto-
somes elicit similar responses in alternate models of gout, such
as the intra-articular or air-pouch model, which are known to
have various degrees of NLRP3, ASC and caspase 1 involvement
in IL-1β release.37
The motivation behind this work was to better understand
the self-limiting nature of gout. This study supports the notion
that resolution of gout is initiated with the release of PMN-Ecto
early on during neutrophil activation. In a broader context,
PMN-Ecto release may limit excessive inﬂammation in response
to exogenous and endogenous danger signals and their patho-
physiological relevance likely extends to conditions other than
gout.38
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